OPERATING PROGRAMME
|
| Grants |
€ 335.000 |
% |
| |
AirLiquide |
€ 30.000 |
9% |
| |
AlkAbello |
€30.000 |
9% |
| |
AstraZeneca |
€30.000 |
9% |
| |
Boehringer Ingelheim |
€30.000 |
9% |
| |
Chiesi |
€ 5.000 |
1% |
| |
GSK |
€ 30.000 |
9% |
| |
Novartis |
€ 30.000 |
9% |
| |
TEVA |
€ 30.000 |
9% |
| |
Stallergenes |
€ 30.000 |
9% |
| |
SigAirHandling |
€ 30.000 |
9% |
| |
Sanofi Genzyme |
€ 30.000 |
9% |
| |
Regeneron |
€ 30.000 |
9% |
| Membership fees |
€ 15.000 |
|
| |
|
|
|
PROJECT PROGRAMME
|
| EFA Projects |
€ 518.000,00 |
|
| |
COPD MOVE GSK |
€ 40.000 |
8% |
| |
COPD MOVE AstraZeneca |
€ 40.000 |
8% |
| |
COPD MOVE Novartis |
€ 23.000 |
4% |
| |
Atopic Eczema Sanofi Genzyme |
€ 176.000 |
34% |
| |
Atopic Eczema Regeneron |
€ 176.000 |
34% |
| |
Capacity Building Novartis |
€ 16.500 |
3% |
| |
Capacity Building Boehringer ingelheim |
€ 16.500 |
3% |
| |
Interest Group EP Novartis |
€ 10.000 |
2% |
| |
Interest Group EP ALK Abello |
€ 10.000 |
2% |
| |
Interest Group EP Stallergens |
€ 10.000 |
2% |